Amir Goldkorn, MD

Title(s)Professor of Medicine
SchoolKeck School of Medicine of Usc
AddressNOR 3444, NRT
Health Sciences Campus
Los Angeles CA 90089-9173
Phone+1 323 442 7721
vCardDownload vCard

    Collapse Biography 
    Collapse Awards and Honors
    Harvard University1990  - 1994Harvard College Scholarship
    UCLA School of Medicine1996  - 1997Letters of Distinction
    American Society of Clinical Oncology2006  - 2007Young Investigator Award
    Stop Cancer Foundation2007  - 2010Research Career Development Award
    American Society of Clinical Oncology2012Merit Award
    Western Society of Clinical Investigation2014Elected Member
    American Federation for Medical Research2015Outstanding Investigator Award
    National Institutes of Health Loan Repayment Program Award

    Collapse Overview 
    Collapse Overview
    Amir Goldkorn, M.D., is the Associate Director of Translational Sciences at USC Norris. He is a Professor of Medicine and Biochemistry & Molecular Medicine at the Keck School of Medicine of the University of Southern California. Dr. Goldkorn obtained his bachelor’s degree from Harvard University (magna cum laude) and his Medical Degree at the University of California, Los Angeles (UCLA), where he also completed his Internal Medicine residency. Subsequently, he trained in Hematology/Oncology at the University of California, San Francisco (UCSF), where he then remained for 3 additional years of postdoctoral research in the laboratory of Elizabeth Blackburn, a Nobel Laureate and discoverer of telomerase, the enzyme that lengthens and protects chromosome ends (telomeres).

    Dr. Goldkorn is a board-certified medical oncologist and physician-scientist who is clinically subspecialized in genitourinary (GU) malignancies. Dr. Goldkorn’s laboratory is focused on developing the therapeutic and biomarker potential of liquid biopsies, cancer plasticity, and telomerase. His team leads liquid biopsy studies in phase III multi-center GU cancer trials sponsored by the NCI-SWOG cooperative group, where Dr. Goldkorn chairs translational medicine for prostate cancer. Dr. Goldkorn founded and directs a Liquid Biopsy Core at USC Norris, which offers state-of-the-art instrumentation and develops novel workflows for multiparametric analysis of liquid biopsies. In the area of cancer plasticity, Dr. Goldkorn’s group discovered that cancer cells can cyclically lose and regain cancer stem-like properties, and their current work is focused on elucidating epigenetic, epitranscriptomic, and metabolomic mechanisms that mediate this plasticity. Collectively, these research efforts are aimed at surmounting cancer heterogeneity and providing powerful new tools for precision cancer care.

    Collapse Research 
    Collapse Research Activities and Funding
    Integrated radiomic and liquid biopsy monitoring in SWOG S1802: A phase 3 therapeutic trial for metastatic prostate cancer
    NIH R01CA257610Feb 9, 2021 - Jan 31, 2026
    Role: Principal Investigator
    Biomarkers of Hormone Therapy Response in a Multicenter Prostate Cancer Trial
    NIH R01CA172436Sep 10, 2014 - Aug 31, 2021
    Role: Principal Investigator
    Circulating Tumor Cell Capture & Analysis in a Multi-Center Prostate Cancer Trial
    NIH R01CA141077Sep 18, 2009 - Nov 30, 2014
    Role: Co-Principal Investigator
    Targeting Cancer with Telomerase Interference
    NIH K08CA126983Sep 1, 2007 - Aug 31, 2012
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Faculty Mentoring

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Markers of bone metabolism and overall survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): A subset analysis of SWOG S1216, a phase III trial of androgen deprivation with or without orteronel. Prostate Cancer Prostatic Dis. 2024 Feb 29. Lara PN, Mayerson E, Gertz E, Tangen C, Goldkorn A, van Loan M, Hussain M, Gupta S, Zhang J, Parikh M, Twardowski P, Quinn DI, LeBlanc M, Thompson I, Agarwal N. PMID: 38424319.
      View in: PubMed   Mentions:    Fields:    
    2. Association of Molecular Subtypes with Pathologic Response, PFS, and OS in a Phase II Study of COXEN with Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. Clin Cancer Res. 2024 01 17; 30(2):444-449. Lerner SP, McConkey DJ, Tangen CM, Meeks JJ, Flaig TW, Hua X, Daneshmand S, Alva AS, Lucia MS, Theodorescu D, Goldkorn A, Milowsky MI, Choi W, Bangs R, Gustafson DL, Plets M, Thompson IM. PMID: 37966367; PMCID: PMC10824507.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    3. m6A epitranscriptome analysis reveals differentially methylated transcripts that drive early chemoresistance in bladder cancer. NAR Cancer. 2023 Dec; 5(4):zcad054. Hodara E, Mades A, Swartz L, Iqbal M, Xu T, Bsteh D, Farnham PJ, Rhie SK, Goldkorn A. PMID: 38023731; PMCID: PMC10653028.
      View in: PubMed   Mentions:
    4. Long-term Outcomes from a Phase 2 Study of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer (SWOG S1314; NCT02177695). Eur Urol. 2023 09; 84(3):341-347. Flaig TW, Tangen CM, Daneshmand S, Alva AS, Lucia MS, McConkey DJ, Theodorescu D, Goldkorn A, Milowsky MI, Bangs R, MacVicar GR, Bastos BR, Fowles JS, Gustafson DL, Plets M, Thompson IM, Lerner SP. PMID: 37414705; PMCID: PMC10659139.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    5. Cell-free DNA Methylation as a Predictive Biomarker of Response to Neoadjuvant Chemotherapy for Patients with Muscle-invasive Bladder Cancer in SWOG S1314. Eur Urol Oncol. 2023 10; 6(5):516-524. Lu YT, Plets M, Morrison G, Cunha AT, Cen SY, Rhie SK, Siegmund KD, Daneshmand S, Quinn DI, Meeks JJ, Lerner SP, Petrylak DP, McConkey D, Flaig TW, Thompson IM, Goldkorn A. PMID: 37087309; PMCID: PMC10587361.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCellsCTClinical Trials
    6. Bone Biomarkers and Subsequent Survival in Men with Hormone-sensitive Prostate Cancer: Results from the SWOG S1216 Phase 3 Trial of Androgen Deprivation Therapy with or Without Orteronel. Eur Urol. 2024 Feb; 85(2):171-176. Lara PN, Mayerson E, Gertz E, Tangen C, Goldkorn A, van Loan M, Hussain M, Gupta S, Zhang J, Parikh M, Twardowski P, Quinn DI, LeBlanc M, Vogelzang NJ, Thompson I, Agarwal N. PMID: 37085425; PMCID: PMC10662935.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    7. Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial). J Clin Oncol. 2023 06 20; 41(18):3352-3362. Morris MJ, Heller G, Hillman DW, Bobek O, Ryan C, Antonarakis ES, Bryce AH, Hahn O, Beltran H, Armstrong AJ, Schwartz L, Lewis LD, Beumer JH, Langevin B, McGary EC, Mehan PT, Goldkorn A, Roth BJ, Xiao H, Watt C, Taplin ME, Halabi S, Small EJ. PMID: 36996380; PMCID: PMC10414728.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    8. External Validation of Association of Baseline Circulating Tumor Cell Counts with Survival Outcomes in Men with Metastatic Castration-Sensitive Prostate Cancer. Mol Cancer Ther. 2022 Dec 02; 21(12):1857-1861. Swami U, Sayegh N, Jo Y, Haaland B, McFarland TR, Nussenzveig RH, Goel D, Sirohi D, Hahn AW, Maughan BL, Goldkorn A, Agarwal N. PMID: 36198026.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCellsCTClinical Trials
    9. Integration of Liquid Biopsies in Clinical Management of Metastatic Prostate Cancer. Curr Oncol Rep. 2022 10; 24(10):1287-1298. Tulpule V, Morrison GJ, Falcone M, Quinn DI, Goldkorn A. PMID: 35575959; PMCID: PMC9474724.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    10. Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216). J Clin Oncol. 2022 10 01; 40(28):3301-3309. Agarwal N, Tangen CM, Hussain MHA, Gupta S, Plets M, Lara PN, Harzstark AL, Twardowski PW, Paller CJ, Zylla D, Zibelman MR, Levine E, Roth BJ, Goldkorn A, Vaena DA, Kohli M, Crispino T, Vogelzang NJ, Thompson IM, Quinn DI. PMID: 35446628; PMCID: PMC9553390.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    11. Bladder cancer cells shift rapidly and spontaneously to cisplatin-resistant oxidative phosphorylation that is trackable in real time. Sci Rep. 2022 04 01; 12(1):5518. Xu T, Junge JA, Delfarah A, Lu YT, Arnesano C, Iqbal M, Delijani K, Hsieh TC, Hodara E, Mehta HH, Cohen P, Graham NA, Fraser SE, Goldkorn A. PMID: 35365706; PMCID: PMC8976067.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    12. FOXC1 Binds Enhancers and Promotes Cisplatin Resistance in Bladder Cancer. Cancers (Basel). 2022 Mar 28; 14(7). Lu YT, Xu T, Iqbal M, Hsieh TC, Luo Z, Liang G, Farnham PJ, Rhie SK, Goldkorn A. PMID: 35406487; PMCID: PMC8996937.
      View in: PubMed   Mentions: 5  
    13. Non-Invasive Profiling of Advanced Prostate Cancer via Multi-Parametric Liquid Biopsy and Radiomic Analysis. Int J Mol Sci. 2022 Feb 25; 23(5). Morrison G, Buckley J, Ostrow D, Varghese B, Cen SY, Werbin J, Ericson N, Cunha A, Lu YT, George T, Smith J, Quinn D, Duddalwar V, Triche T, Goldkorn A. PMID: 35269713; PMCID: PMC8910093.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    14. A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695). Clin Cancer Res. 2021 05 01; 27(9):2435-2441. Flaig TW, Tangen CM, Daneshmand S, Alva A, Lerner SP, Lucia MS, McConkey DJ, Theodorescu D, Goldkorn A, Milowsky MI, Bangs R, MacVicar GR, Bastos BR, Fowles JS, Gustafson DL, Plets M, Thompson IM. PMID: 33568346; PMCID: PMC8219246.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCTClinical Trials
    15. Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216). Clin Cancer Res. 2021 04 01; 27(7):1967-1973. Goldkorn A, Tangen C, Plets M, Morrison GJ, Cunha A, Xu T, Pinski JK, Ingles SA, Triche T, Harzstark AL, Kohli M, MacVicar GR, Vaena DA, Crispino AW, McConkey DJ, Lara PN, Hussain MHA, Quinn DI, Vogelzang NJ, Thompson IM, Agarwal N. PMID: 33500355; PMCID: PMC8026618.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCellsCTClinical Trials
    16. Cancer transcriptomic profiling from rapidly enriched circulating tumor cells. Int J Cancer. 2020 05 15; 146(10):2845-2854. Morrison GJ, Cunha AT, Jojo N, Xu Y, Xu Y, Kwok E, Robinson P, Dorff T, Quinn D, Carpten J, Manojlovic Z, Goldkorn A. PMID: 32037533; PMCID: PMC7451020.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    17. Epigenetic plasticity potentiates a rapid cyclical shift to and from an aggressive cancer phenotype. Int J Cancer. 2020 06 01; 146(11):3065-3076. Xu T, Li HT, Wei J, Li M, Hsieh TC, Lu YT, Lakshminarasimhan R, Xu R, Hodara E, Morrison G, Gujar H, Rhie SK, Siegmund K, Liang G, Goldkorn A. PMID: 32017074; PMCID: PMC7448727.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    18. Current status of liquid biopsies for the detection and management of prostate cancer. Cancer Manag Res. 2019; 11:5271-5291. Lu YT, Delijani K, Mecum A, Goldkorn A. PMID: 31239778; PMCID: PMC6559244.
      View in: PubMed   Mentions: 28  
    19. Randomized Phase II Trial of Abiraterone Alone or With Dasatinib in Men With Metastatic Castration-resistant Prostate Cancer (mCRPC). Clin Genitourin Cancer. 2019 08; 17(4):241-247.e1. Dorff TB, Quinn DI, Pinski JK, Goldkorn A, Sadeghi S, Tsao-Wei D, Groshen S, Kuhn P, Gross ME. PMID: 31227432; PMCID: PMC7446934.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCellsCTClinical Trials
    20. Multiparametric liquid biopsy analysis in metastatic prostate cancer. JCI Insight. 2019 03 07; 4(5). Hodara E, Morrison G, Cunha A, Zainfeld D, Xu T, Xu Y, Dempsey PW, Pagano PC, Bischoff F, Khurana A, Koo S, Ting M, Cotter PD, Moore MW, Gunn S, Usher J, Rabizadeh S, Danenberg P, Danenberg K, Carpten J, Dorff T, Quinn D, Goldkorn A. PMID: 30702443; PMCID: PMC6483502.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCells
    21. A phase I trial of topotecan plus tivantinib in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2018 10; 82(4):723-732. Liu SV, Groshen SG, Kelly K, Reckamp KL, Belani C, Synold TW, Goldkorn A, Gitlitz BJ, Cristea MC, Gong IY, Semrad TJ, Xu Y, Xu T, Koczywas M, Gandara DR, Newman EM. PMID: 30128950; PMCID: PMC6342617.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    22. Development of a translational medicine protocol for an NCTN genitourinary clinical trial: Critical steps, common pitfalls and a basic guide to translational clinical research. Urol Oncol. 2019 05; 37(5):313-317. Meeks JJ, Goldkorn A, Aparicio AM, McConkey DJ. PMID: 30115512; PMCID: PMC6886001.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    23. Bone turnover biomarkers identify unique prognostic risk groups in men with castration resistant prostate cancer and skeletal metastases: Results from SWOG S0421. Cancer Treat Res Commun. 2018; 16:18-23. Lara PN, Plets M, Tangen C, Gertz E, Vogelzang NJ, Hussain M, Twardowski PW, Garzotto MG, Monk JP, Carducci M, Goldkorn A, Mack PC, Thompson I, Van Loan M, Quinn DI. PMID: 31298998; PMCID: PMC6628720.
      View in: PubMed   Mentions: 4     Fields:    
    24. Development and Application of Liquid Biopsies in Metastatic Prostate Cancer. Curr Oncol Rep. 2018 03 23; 20(4):35. Morrison GJ, Goldkorn A. PMID: 29572775; PMCID: PMC7446728.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCells
    25. Liquid Biopsy in Prostate Cancer: Circulating Tumor Cells and Beyond. Cancer Treat Res. 2018; 175:87-104. Zainfeld D, Goldkorn A. PMID: 30168118; PMCID: PMC7450827.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    26. The evolution of chemotherapy for the treatment of prostate cancer. Ann Oncol. 2017 Nov 01; 28(11):2658-2669. Quinn DI, Sandler HM, Horvath LG, Goldkorn A, Eastham JA. PMID: 29045523.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    27. Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421. Clin Genitourin Cancer. 2017 12; 15(6):635-641. Sonpavde G, Pond GR, Plets M, Tangen CM, Hussain MHA, Lara PN, Goldkorn A, Garzotto MG, Mack PC, Higano CS, Vogelzang NJ, Thompson IM, Twardowski PW, Van Veldhuizen PJ, Agarwal N, Carducci MA, Monk JP, Quinn DI. PMID: 28579151; PMCID: PMC5734863.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    28. Circulating Tumor Cells in Genitourinary Malignancies: An Evolving Path to Precision Medicine. Front Oncol. 2017; 7:6. Hugen CM, Zainfeld DE, Goldkorn A. PMID: 28191452; PMCID: PMC5269447.
      View in: PubMed   Mentions: 5  
    29. Telomere and Telomerase Therapeutics in Cancer. Genes (Basel). 2016 May 26; 7(6). Xu Y, Goldkorn A. PMID: 27240403; PMCID: PMC4929421.
      View in: PubMed   Mentions: 47     Fields:    
    30. AXIN2 expression predicts prostate cancer recurrence and regulates invasion and tumor growth. Prostate. 2016 May; 76(6):597-608. Hu BR, Fairey AS, Madhav A, Yang D, Li M, Groshen S, Stephens C, Kim PH, Virk N, Wang L, Martin SE, Erho N, Davicioni E, Jenkins RB, Den RB, Xu T, Xu Y, Gill IS, Quinn DI, Goldkorn A. PMID: 26771938; PMCID: PMC7455032.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    31. Editorial Comment. J Urol. 2015 Sep; 194(3):798. Goldkorn A. PMID: 26072034.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    32. Exosome-mediated transfer of microRNAs within the tumor microenvironment and neuroblastoma resistance to chemotherapy. J Natl Cancer Inst. 2015 Jul; 107(7). Challagundla KB, Wise PM, Neviani P, Chava H, Murtadha M, Xu T, Kennedy R, Ivan C, Zhang X, Vannini I, Fanini F, Amadori D, Calin GA, Hadjidaniel M, Shimada H, Jong A, Seeger RC, Asgharzadeh S, Goldkorn A, Fabbri M. PMID: 25972604; PMCID: PMC4651042.
      View in: PubMed   Mentions: 190     Fields:    Translation:HumansCells
    33. Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer. 2015 Apr 15; 136(8):1856-62. Goldkorn A, Ely B, Tangen CM, Tai YC, Xu T, Li H, Twardowski P, Veldhuizen PJ, Agarwal N, Carducci MA, Monk JP, Garzotto M, Mack PC, Lara P, Higano CS, Hussain M, Vogelzang NJ, Thompson IM, Cote RJ, Quinn DI. PMID: 25219358; PMCID: PMC4323674.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCellsCTClinical Trials
    34. Circulating tumor cells in prostate cancer: a better predictor of survival than prostate specific antigen? Expert Rev Anticancer Ther. 2014 Nov; 14(11):1257-60. Hu B, Goldkorn A. PMID: 25199875.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    35. New prostate cancer drugs: extending and improving life. Lancet Oncol. 2014 Sep; 15(10):1052-4. Agarwal N, Dorff T, Goldkorn A. PMID: 25104108.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    36. Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol. 2014 Apr 10; 32(11):1136-42. Goldkorn A, Ely B, Quinn DI, Tangen CM, Fink LM, Xu T, Twardowski P, Van Veldhuizen PJ, Agarwal N, Carducci MA, Monk JP, Datar RH, Garzotto M, Mack PC, Lara P, Higano CS, Hussain M, Thompson IM, Cote RJ, Vogelzang NJ. PMID: 24616308; PMCID: PMC3970171.
      View in: PubMed   Mentions: 144     Fields:    Translation:HumansCellsCTClinical Trials
    37. Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: results from SWOG 0421. J Natl Cancer Inst. 2014 Apr; 106(4):dju013. Lara PN, Ely B, Quinn DI, Mack PC, Tangen C, Gertz E, Twardowski PW, Goldkorn A, Hussain M, Vogelzang NJ, Thompson IM, Van Loan MD. PMID: 24565955; PMCID: PMC3982883.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCTClinical Trials
    38. Circulating tumor cells in prostate cancer. Cancers (Basel). 2013 Dec 04; 5(4):1676-90. Hu B, Rochefort H, Goldkorn A. PMID: 24305656; PMCID: PMC3875960.
      View in: PubMed   Mentions: 21  
    39. Efficacy of oxaliplatin plus pemetrexed in chemotherapy pretreated metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2013 Dec; 11(4):416-22. Dorff TB, Tsao-Wei DD, Groshen S, Boswell W, Goldkorn A, Xiong S, Quinn DI, Pinski JK. PMID: 24099865.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    40. Cancer cells acquire a drug resistant, highly tumorigenic, cancer stem-like phenotype through modulation of the PI3K/Akt/β-catenin/CBP pathway. Int J Cancer. 2014 Jan 01; 134(1):43-54. He K, Xu T, Xu Y, Ring A, Kahn M, Goldkorn A. PMID: 23784558.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansCells
    41. Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. Lancet Oncol. 2013 Aug; 14(9):893-900. Quinn DI, Tangen CM, Hussain M, Lara PN, Goldkorn A, Moinpour CM, Garzotto MG, Mack PC, Carducci MA, Monk JP, Twardowski PW, Van Veldhuizen PJ, Agarwal N, Higano CS, Vogelzang NJ, Thompson IM. PMID: 23871417; PMCID: PMC4277263.
      View in: PubMed   Mentions: 78     Fields:    Translation:HumansCTClinical Trials
    42. Therapeutic windows and opportunity cost cast upon prostate cancer's fatal shore. Ann Oncol. 2013 Jul; 24(7):1717-1720. Goldkorn A, Aparicio AM, Quinn DI. PMID: 23798673.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    43. Perillyl alcohol for the treatment of temozolomide-resistant gliomas. Mol Cancer Ther. 2012 Nov; 11(11):2462-72. Cho HY, Wang W, Jhaveri N, Torres S, Tseng J, Leong MN, Lee DJ, Goldkorn A, Xu T, Petasis NA, Louie SG, Schönthal AH, Hofman FM, Chen TC. PMID: 22933703.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansAnimalsCells
    44. Telomerase targeted therapy in cancer and cancer stem cells. Clin Adv Hematol Oncol. 2011 Jun; 9(6):442-55. Xu Y, He K, Goldkorn A. PMID: 21841744.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimalsCells
    45. Cancer cells cyclically lose and regain drug-resistant highly tumorigenic features characteristic of a cancer stem-like phenotype. Mol Cancer Ther. 2011 Jun; 10(6):938-48. He K, Xu T, Goldkorn A. PMID: 21518726; PMCID: PMC3112267.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansAnimalsCells
    46. Prostate tumor cells with cancer progenitor properties have high telomerase activity and are rapidly killed by telomerase interference. Prostate. 2011 Sep 15; 71(13):1390-400. Xu T, He K, Wang L, Goldkorn A. PMID: 21321978; PMCID: PMC3123672.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimalsCells
    47. A cancer detection platform which measures telomerase activity from live circulating tumor cells captured on a microfilter. Cancer Res. 2010 Aug 15; 70(16):6420-6. Xu T, Lu B, Tai YC, Goldkorn A. PMID: 20663903; PMCID: PMC2922429.
      View in: PubMed   Mentions: 57     Fields:    Translation:HumansCells
    48. Reprogramming murine telomerase rapidly inhibits the growth of mouse cancer cells in vitro and in vivo. Mol Cancer Ther. 2010 Feb; 9(2):438-49. Xu T, Xu Y, Liao CP, Lau R, Goldkorn A. PMID: 20124445; PMCID: PMC2820598.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimalsCells
    49. Targeted therapy in renal cancer. Ther Adv Med Oncol. 2009 Nov; 1(3):183-205. Dorff TB, Goldkorn A, Quinn DI. PMID: 21789121; PMCID: PMC3125999.
      View in: PubMed   Mentions: 10  
    50. Assembly of mutant-template telomerase RNA into catalytically active telomerase ribonucleoprotein that can act on telomeres is required for apoptosis and cell cycle arrest in human cancer cells. Cancer Res. 2006 Jun 01; 66(11):5763-71. Goldkorn A, Blackburn EH. PMID: 16740715.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCells
    51. Cortical variability and asymmetry in normal aging and Alzheimer's disease. Cereb Cortex. 1998 Sep; 8(6):492-509. Thompson PM, Moussai J, Zohoori S, Goldkorn A, Khan AA, Mega MS, Small GW, Cummings JL, Toga AW. PMID: 9758213.
      View in: PubMed   Mentions: 72     Fields:    Translation:Humans
    52. Sulcal variability in the Alzheimer's brain: correlations with cognition. Neurology. 1998 Jan; 50(1):145-51. Mega MS, Thompson PM, Cummings JL, Back CL, Xu ML, Zohoori S, Goldkorn A, Moussai J, Fairbanks L, Small GW, Toga AW. PMID: 9443471.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    Amir's Networks
    Concepts (213)
    Derived automatically from this person's publications.
    Co-Authors (33)
    People in Profiles who have published with this person.
    Similar People (60)
    People who share similar concepts with this person.
    Same Department
    Search Department